Hypertension

Results of the CHAP project demonstrate active treatment of chronic mild hypertension was associated with reductions in risk of adverse pregnancy outcomes and is unlikely to harm the developing child.

A pilot study presented at ACC.22 demonstrates the impact of implementation of an RPM program to improve blood pressure control in patients with hypertension at primary care clinics.

Large variations were observed in the transition between monotherapy and dual combination therapy for hypertension across countries and demographic group.

Deep learning analyses of photographic images and other test results in clinical trials may reduce cost and improve the consistency and accuracy of end point assessments.

Patients with tachyarrhythmia or hypertension as their underlying trigger of type 2 MI had a lower mortality than patients with hypotension, hypoxemia, or anemia.

A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.

Findings from REDUCE-IT show icosapent ethyl was projected to be cost-effective compared with standard care in patients with high CV risk despite statin therapy.

A pilot trial suggests telemedicine methods need to be tailored to reach adversely affected populations including Black patients on Medicare or Medicaid.

Data show atherosclerotic burden was heterogeneous across LDL-C levels and risk is shown to be consistently associated with plaque burden.

Data from the PATH-BP study suggests patients receiving daily acetaminophen experienced significant increases in systolic and diastolic blood pressure after just 2 weeks of receiving the medication.

The NDA has been assigned standard review with a PDUFA target action date in late November 2022.

No difference was observed between atrial shunt placement and sham in the endpoint of CVD death, non-fatal ischemic stroke at 12 months, and rate of total heart failure events at 24 months.

Knowing the symptoms and risk factors of CVD unique to women can aid in awareness and prevention efforts.

Women with high social isolation and high loneliness scores had a 13.0% - 27.0% higher risk of incident CVD compared to women with low scores.

Dr. Radhakrishnan discusses both the effects of gender bias and why women don't get screened for heart disease.

On Wear Red Day, Dr. Ivanova advocates for increased awareness and diversity in women's cardiovascular care.

Rates of aspirin use for preeclampsia prophylaxis were observed in a minority of women with risk factors including pre-pregnancy diabetes, obesity, or chronic hypertension.

An analysis of the National Inpatient Sample suggests the rates of hospitalization for hypertension crises increased from 2002 to 2015, but the rate of in-hospital death during these crises decreased during the same period.

There was not an association between sleep duration and metabolic diseases found in men.

The new guidelines conclude that current evidence is insufficient to assess the balance of benefits and harms of screening for AF in adults ≥50 years.

Early-pregnancy NT-proBNP level may be an important determinant of pregnancy outcomes and CV risk.

A recent analysis of data from more than 4000 women suggests higher NT-proBNP concentrations during early pregnancy were associated with a 19% reduction in risk of HDP and a 16% reduction in risk of hypertension 2-7 years after delivery.

Data show the change in CHD prevalence from 2011 - 2018 (6.2% to 6.0%) was statistically insignificant.

Data show among patients with focal FDG uptake, PET/MRI and inflammatory blood markers resolved at follow-up performed at a mean of 52 days after baseline.

A retrospective cohort analysis of more than 3000 patients with CKD suggests use of MRAs was significantly associated with a reduction in the need for renal replacement therapy.

Data show the 1-year incidence of the composite primary endpoint was 10.6% among patients randomized to FFR-guided PCI and 6.9% in CABG.

Sexual activity was involved in 0.2% of all SCDs, with sudden arrhythmic death syndrome and cardiomyopathies predominant underlying causes.

Abbott's device is designed to create highly detailed 3-dimensional maps of the heart to help physicians identify and treat abnormal rhythms.

Data show Black and White patients had a similar risk of MACE over a median 24.4-month follow-up.

From the pooled results of TRILOGY 1 and 2, data show 4 g/d of ω-3–PL/FFA reduced TG levels by 10.9% at 12 weeks and 12.7% at 26 weeks, relative to placebo.